US Stock MarketDetailed Quotes
ADCT ADC Therapeutics
- 1.890
- -0.090-4.55%
Close Dec 13 16:00 ET
- 1.880
- -0.010-0.53%
Post 19:50 ET
182.74MMarket Cap-0.79P/E (TTM)
2.010High1.800Low1.47MVolume2.000Open1.980Pre Close2.81MTurnover1.92%Turnover RatioLossP/E (Static)96.69MShares6.04052wk High-1.06P/B145.22MFloat Cap1.18052wk Low--Dividend TTM76.83MShs Float56.590Historical High--Div YieldTTM10.61%Amplitude0.360Historical Low1.907Avg Price1Lot Size
ADC Therapeutics Stock Forum
Sign in to post a comment
Reminder to my self. I have lost half of the profit. Keep discipline and stick to the rules
5
2
Please take note of the following acronyms
NFA = not financial advice
RTH = regular trading hours
AH = after hours
LTB = left to borrow
CTB = cost to borrow
*I removed $AmpliTech Group (AMPG.US)$ because it just announced direct offering of $2M valued $1.6/shares. Now there are offerings where market defies it and continues to rally. We shall see tomorrow
$Nuburu (BURU.US)$ PR AH 12/11: Resolved compliance issue. Up AH. Low float. CTB...
NFA = not financial advice
RTH = regular trading hours
AH = after hours
LTB = left to borrow
CTB = cost to borrow
*I removed $AmpliTech Group (AMPG.US)$ because it just announced direct offering of $2M valued $1.6/shares. Now there are offerings where market defies it and continues to rally. We shall see tomorrow
$Nuburu (BURU.US)$ PR AH 12/11: Resolved compliance issue. Up AH. Low float. CTB...
105
38
2
$ADC Therapeutics (ADCT.US)$
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Wednesday, 11th December at 7:30 am
ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate
Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-g...
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Wednesday, 11th December at 7:30 am
ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate
Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-g...
2
$ADC Therapeutics (ADCT.US)$
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
ADC Therapeutics announced updated data from two clinical trials evaluating ZYNLONTA®. In the first trial, ZYNLONTA combined with rituximab for relapsed/refractory follicular lymphoma showed a 97.4% overall response rate and 76.9% complete response rate, with 12-m...
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
ADC Therapeutics announced updated data from two clinical trials evaluating ZYNLONTA®. In the first trial, ZYNLONTA combined with rituximab for relapsed/refractory follicular lymphoma showed a 97.4% overall response rate and 76.9% complete response rate, with 12-m...
Day trading is a fast paced trading strategy where traders aim to profit from short term price movements within a single trading day. Unlike swing trading, which involves holding positions for days or weeks, day traders close all trades before the market closes to avoid overnight risks such as earnings announcements or geopolitical events that could impact stock prices.
This strategy relies heavily on technical analysis, with traders using charts, patterns, and indicators li...
This strategy relies heavily on technical analysis, with traders using charts, patterns, and indicators li...
5
$ADC Therapeutics (ADCT.US)$ ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
PR Newswire· 6 mins ago
Company to host corporate update webcast to share results on December 11, 2024
LAUSANNE, Switzerland, Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m. EST to provide an update on preliminary data from the LOTIS-7Phase 1b open-label...
PR Newswire· 6 mins ago
Company to host corporate update webcast to share results on December 11, 2024
LAUSANNE, Switzerland, Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m. EST to provide an update on preliminary data from the LOTIS-7Phase 1b open-label...
2
$ADC Therapeutics (ADCT.US)$
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
ADC Therapeutics (NYSE: ADCT) announced two investigator-initiated study abstracts on ZYNLONTA accepted for presentation at the 66th ASH Annual Meeting. The Phase 2 study combining ZYNLONTA with rituximab in relapsed/refractory follicular lymphomashowed a 97.1% overall response rate among 35 patients, with an 80% best complete metabolic respon...
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
ADC Therapeutics (NYSE: ADCT) announced two investigator-initiated study abstracts on ZYNLONTA accepted for presentation at the 66th ASH Annual Meeting. The Phase 2 study combining ZYNLONTA with rituximab in relapsed/refractory follicular lymphomashowed a 97.1% overall response rate among 35 patients, with an 80% best complete metabolic respon...
$Esperion Therapeutics (ESPR.US)$ Along with this! I will also be looking towards $Wheels Up Experience (UP.US)$ & $ADC Therapeutics (ADCT.US)$ ! There is a number of others PM. But these 3 is where i will be looking a bit more intently! Hehehe. NFA Just thinking outloud ![]()
2
5
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$ADC Therapeutics (ADCT.US)$ ADC Therapeutics SA: Lotis-7 Trial Enrollment on Track With Efficacy and Safety Data on Eligible Patients Expected by Year-End 2024
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
102539778 : nah this was just criming
hotboyz : it's going up now